DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Onartuzumab is an investigational drug.
There have been 15 clinical trials for Onartuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2012.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and M.D. Anderson Cancer Center.
There are fourteen US patents protecting this investigational drug and four hundred and fifty-three international patents.
Recent Clinical Trials for Onartuzumab
|An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study||Hoffmann-La Roche||Phase 3|
|Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)||Genentech, Inc.||Phase 1/Phase 2|
|Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)||M.D. Anderson Cancer Center||Phase 1/Phase 2|
Top disease conditions for Onartuzumab
Top clinical trial sponsors for Onartuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Onartuzumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Onartuzumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Onartuzumab||Start Trial||Cancer treatment with c-met antagonists and correlation of the latter with HGF expression||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|Onartuzumab||Start Trial||Methods of treating glioblastoma multiforme using ibudilast||MediciNova, Inc. (La Jolla, CA)||Start Trial|
|Onartuzumab||Start Trial||Method for predicting efficacy of c-Met inhibitor||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||Start Trial|
|Onartuzumab||Start Trial||Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Onartuzumab||European Patent Office||2954056||2033-02-08||Start Trial|
|Onartuzumab||Hong Kong||1218930||2033-02-08||Start Trial|
|Onartuzumab||World Intellectual Property Organization (WIPO)||2014124326||2033-02-08||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|